Michael Peel
20Patents
5h-index
80Co-inventors
72Inventor score
Filing activity: Apr 6, 1990 → Sep 16, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6268391A | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | Chemistry; Metallurgy | 83 | Expired |
| US7470787B2 | Isoquinoline compounds | Human Necessities | 46 | Active |
| US7189712B2 | 1,3-Oxazole compounds for the treatment of cancer | Chemistry; Metallurgy | 9 | Expired |
| US7166597B2 | Fused pyrazole derivatives being protein kinase inhibitors | Human Necessities | 7 | Expired |
| US6964977B2 | Oxindole derivatives | Chemistry; Metallurgy | 5 | Expired |
| US6100273A | Water soluble camptothecin derivatives | Chemistry; Metallurgy | 5 | Expired |
| US7863465B2 | Antifungal agents | Human Necessities | 5 | Active |
| US7109209B2 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | Human Necessities | 4 | Expired |
| US7034030B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | Human Necessities | 4 | Expired |
| US7279473B2 | Pyrazolopyridazine derivatives | Human Necessities | 3 | Expired |
| US5144034A | Process for the synthesis of cyclopentene derivatives of purines | Chemistry; Metallurgy | 1 | Expired |
| US8536114B2 | Macrocycles | Human Necessities | 1 | Active |
| US8614221B2 | Inhibitors of Akt activity | Chemistry; Metallurgy | 1 | Active |
| US8222255B2 | Antifungal agents | Human Necessities | 0 | Active |
| US10738084B2 | Macrocycles | Human Necessities | 0 | Active |
| US7163940B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | Human Necessities | 0 | Expired |
| US12060440B2 | Cyclophilin inhibitors and uses thereof | Human Necessities | 0 | Active |
| US9090671B2 | Macrocyclic peptides | Human Necessities | 0 | Active |
| US12350310B2 | Treatment and prevention of nephrotoxin-induced kidney injuries | Human Necessities | 0 | Active |
| US11918581B2 | Combination therapy comprising JAK pathway inhibitor and rock inhibitor | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.